Researchers from Rutgers Health and other institutions have discovered why a powerful leukemia drug eventually fails in most patients—and found a potential way to overcome that resistance. Subscribe ...

Cancers driven by hiccups in RNA processing can’t hide from our immune system, according to new work published today in Cell. A cross-institutional team Fred Hutch Cancer Center and Memorial Sloan ...

In a new study presented at the American Association for Cancer Research (AACR) Annual Meeting and published in Blood Cancer Discovery, titled, “Single-cell Transcriptional Atlas of Human ...

A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and potential therapeutic targets. The team used their reference map for normal ...

One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy—and an aggressive type of blood cancer called acute myeloid leukemia (AML) is notorious for this.

Researchers identify beta catenin protein degradation as a therapeutic vulnerability in B cell acute lymphoblastic leukaemia, supporting the repurposing of glycogen synthase kinase 3 beta inhibitors.

An expert discusses IL-18-armored CAR T cells for adults with relapsed B-cell leukemia, showing complete remissions with manageable side effects. In an onsite interview with CURE at the 2025 ASH ...

Dr. Dima El-Sharkawi discusses how hairy cell leukemia typically presents in patients and the challenges clinicians face in identifying the disease early. At the Hairy Cell Leukemia Foundation 2025 ...

Always in the best of spirits and with a very strong faith, Jamon Tavio King is facing a battle with a very rare leukemia […] ...